We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Marina Biotech Announces Issuance of a U.S. Patent Broadly Covering its Amphoteric Liposomal siRNA Delivery Technology


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Marina Biotech Announces Issuance of a U.S. Patent Broadly Covering its Amphoteric Liposomal siRNA Delivery Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Marina Biotech, Inc. has announced that the U.S. Patent and Trademark Office has issued patent U.S. 7,780,983 covering processes for preparing amphoteric liposomes or SMARTICLES®. Marina Biotech recently acquired the SMARTICLES® intellectual property portfolio of Novosom AG, further expanding its RNA delivery platform intellectual property estate.

Amphoteric liposomes define a novel class of liposomes, which are charge-reversible particles that provide for the delivery of a nucleic acid payload to the cytoplasm, or interior, of a cell either by local or systemic administration. These novel liposomal vectors are designed to release their nucleic acid payload within the target cell where the nucleic acid can then engage a number of biological pathways including the RNA interference pathway and thereby exert a therapeutic effect.

"We are pleased that our recent acquisitions are already generating value for us on the intellectual property front," stated J. Michael French, President and CEO at Marina Biotech. "This patent, covering amphoteric liposomal delivery, is a significant addition to our existing RNA delivery intellectual property estate that also includes the DiLA2 delivery platform, the tkRNAi platform (bacterial delivery platform) and our peptide nanoparticle delivery platform. We will continue to expand our IP position by aggressively seeking issued claims and developing additional novel formulations for safe and effective systemic and local delivery of RNA-based therapeutics."

This patent issuance further secures Marina Biotech's patent position around amphoteric liposomal delivery technology by providing protection to processes by which amphoteric liposomes are prepared. This new U.S. patent adds to the Company's existing world-wide IP portfolio, which provides broad patent protection for amphoteric liposome formulations and novel lipid compounds.
Advertisement